Immunovant Inc - Asset Resilience Ratio

Latest as of September 2019: 98.50%

Immunovant Inc (IMVT) has an Asset Resilience Ratio of 98.50% as of September 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

$116.02 Million

Cash + Short-term Investments

Total Assets

$117.79 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (None–None)

This chart shows how Immunovant Inc's Asset Resilience Ratio has changed over time. Check IMVT PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Immunovant Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Immunovant Inc market cap and net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$116.02 Million	98.5%
Total Liquid Assets	$116.02 Million	98.50%

Asset Resilience Insights

Very High Liquidity: Immunovant Inc maintains exceptional liquid asset reserves at 98.50% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Immunovant Inc Industry Peers by Asset Resilience Ratio

Compare Immunovant Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	10.93%
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.11%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Apogee Therapeutics, Inc. Common Stock NASDAQ:APGE	Biotechnology	47.01%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Beijing Hotgen Biotech Co Ltd SHG:688068	Biotechnology	20.87%

Annual Asset Resilience Ratio for Immunovant Inc (None–None)

The table below shows the annual Asset Resilience Ratio data for Immunovant Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
No yearly data available.

pp = percentage points

About Immunovant Inc

NASDAQ:IMVT USA Biotechnology

Market Cap

$7.86 Billion

Market Cap Rank

#3182 Global

#1133 in USA

Share Price

$38.62

Change (1 day)

-2.18%

52-Week Range

$14.69 - $41.09

All Time High

$52.71